Skip to content
lifestyle.trondstidkontroll.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Olema Oncology
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
May 22, 2026
Olema Oncology to Participate in Upcoming Investor Conferences
May 21, 2026
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
May 20, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
April 29, 2026
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
April 21, 2026
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
April 17, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 2, 2026
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
March 17, 2026
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
March 16, 2026
1
2
Next Page
→